Cookie Einstellungen
Diese Webseite verwendet ausschließlich notwendige Cookies, die für die Funktion erforderlich sind. Marketing- und Statistik-Cookies kommen nicht zum Einsatz. Weitere Informationen finden Sie in unserer Datenschutzerklärung.
 Notwendig   Details einblenden
      OK      
Bitte logge Dich ein, um diese Funktion zu nutzen!
      OK      
x

HENGRUI Aktie

 >HENGRUI Aktienkurs 
7.35 EUR    (TradegateBSX)
Ask: 7.45 EUR / 801 Stück
Bid: 7.25 EUR / 832 Stück
Tagesumsatz: 0 Stück
Realtime Kurs von 7:30 bis 22 Uhr!
HENGRUI Aktie über LYNX handeln
>HENGRUI Performance
1 Woche: +0,7%
1 Monat: +5,8%
3 Monate: -9,5%
6 Monate: -28,6%
1 Jahr: 0%
laufendes Jahr: -5,8%
>HENGRUI Aktie
Name:  JIANGSU HENGRUI PHARMACEUTICALS
Land:  China
Sektor:  Gesundheit
ISIN/ Wkn:  CNE100006XS6 / A41984
Symbol/ Ticker:  0BO (Frankfurt)
Kürzel:  FRA:0BO, ETR:0BO, 0BO:GR
Index:  -
Webseite:  https://www.hengrui.com/
Profil:  Jiangnan Group Limited is an investment holding company principally engaged in the manufacture and trading of wires and cables in the People's Republic of China. It operates through four main segments: power cables for transmission and distribution s..
>Volltext..
Marktkapitalisierung:  48012.34 Mio. EUR
Unternehmenswert:  43189.59 Mio. EUR
Umsatz:  3818.28 Mio. EUR
EBITDA:  1080.61 Mio. EUR
Nettogewinn:  929.77 Mio. EUR
Gewinn je Aktie:  -
Schulden:  116.26 Mio. EUR
Liquide Mittel:  5076.55 Mio. EUR
Operativer Cashflow:  1377.82 Mio. EUR
Bargeldquote:  6.45
Umsatzwachstum:  -0.47%
Gewinnwachstum:  7.08%
Dividende je Aktie:  -
Dividendenrendite:  -
Dividendenschätzung:  -
Insiderhandel:  -
Suchwörter:  HENGRUI
Letzte Datenerhebung:  04.04.26
>HENGRUI Kennzahlen
Aktien/ Unternehmen:
Aktien: 258.2 Mio. St.
Frei handelbar: 95.03%
Leerverk. Aktien: -
Rückkaufquote: 0.27%
Mitarbeiter: -
Umsatz/Mitarb.: -
Analysten:
Analystenrating: Buy
Kursziel: 27.05%
Bewertung:
KGV: -
KGV lG: 41.1
KUV: -
KBV: 6.68
PEG-Ratio: -
EV/EBITDA: 39.97
Rentabilität:
Bruttomarge: 84.96%
Gewinnmarge: 24.35%
Operative Marge: 25.32%
Managementeffizenz:
Gesamtkaprendite: 12.74%
Eigenkaprendite: 14.32%
>HENGRUI Peer Group
Gesundheit, Medizinprodukte & -technik/ Implantate/ Wundpflege
 
30.03.26 - 15:39
Hengrui Pharma and Braveheart Bio Announce Positive Phase 2 Results with HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy (PR Newswire)
 
Results of dose-ranging study suggest potential for best-in-class clinical profile across efficacy, safety and ease of use, including simplified dosing regimen with minimal to no titration necessary HRS-1893 treatment resulted in rapid and substantial reductions in left ventricular......
26.03.26 - 02:00
Results: Hengrui Medicine Last Year's Net Profit RMB7.711 Billion, Up 21.7%; Final Dividend 20 Cents (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
26.03.26 - 01:54
Hengrui Pharma Announces Strong 2025 Annual Results (PR Newswire)
 
SHANGHAI, March 25, 2026 /PRNewswire/ -- On March 25, 2026, Hengrui Pharma (600276.SH; 01276.HK) announced robust financial results for the full year 2025, fueled by its dual strategy of innovation and globalization. Revenue increased 13% year-on-year to RMB 31.63 billion, and net profit......
24.03.26 - 11:30
HK Govt Appoints 4 New Members to Chief Executive's Council of Advisers, Including Chairmen of HENGRUI PHARMA, BIREN TECH, BIDU-SW (AAStocks)
 
The HKSAR Government announced today (24th) the appointment of four new members to the Chief Executive's Council of Advisers. The term will take effect from April 1, 2026, and end on June 30, 2027. The appointees include Sun Piaoyang, Chairman of HENGRUI PHARMA (01276.HK); Xu Tao, Founder and CEO of StarFive Technology; Zhan......
16.02.26 - 05:00
Research: Nomura Keeps Buy on HENGRUI PHARMA But Pares TP to HKD87.49; 2026 NP Expected to Surge 30% (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
10.02.26 - 21:24
Hengrui, Kailera phase 2 obesity pill results could pressure Eli Lilly′s orforglipron (SeekingAlpha)
 
Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...
28.01.26 - 06:30
Research: Daiwa Lists Top Picks in HK Stock Mkt (Table) (AAStocks)
 
StockTENCENT (00700.HK)SHENZHOU INTL (02313.HK)WEICHAI POWER (02338.HK)CHINA RES LAND (01109.HK)BABA-W (09988.HK)MIDEA GP (000333.SZ)NAURA (002371.SZ)CATL (300750.SZ)HENGRUI PHARMA (600276.SH)LQKJ (688008.SH)Trip.com Group (TCOM.US)~AAStocks Financial NewsWebsite: www.aastocks.com...
27.01.26 - 04:00
Research: M Stanley Lowers Rev./ NP Forecasts for HENGRUI PHARMA , Elevates TP to $92 (AAStocks)
 
Morgan Stanley lowered its 2025-2027 total revenue forecasts for HENGRUI PHARMA (01276.HK) by 2.1%/ 3.7%/ 1.8% each, primarily reflecting lower commercial development income from GlaxoSmithKline (GSK) assets and a decline in contributions from the generic drug business, partially offset by higher innovative drug sales forecasts.......
05.01.26 - 05:45
Research: Daiwa Names INNOVENT BIO as Top Pick Alongside HENGRUI PHARMA w/ TP Lifted to HKD112 (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
04.12.25 - 06:15
H Shrs: HSI Leaps 48 Pts at Midday; Robotics Concept Hyped Up (AAStocks)
 
The HSI concluded the midday up 48 points or 0.2% at 25,809. The HSCEI rose 34 points or 0.4% to 9,062. The HSTECH climbed 32 points or 0.6% to 5,567. The total half-day turnover for the market amounted to HKD92.278 billion.In the FTSE China 50 Index review, CHINAHONGQIAO (01378.HK), CATL (03750.HK), and HENGRUI PHARMA (01276.HK......
04.12.25 - 03:15
H Shrs: HSI Opens 43 Pts Higher; ZIJIN MINING, CHINAHONGQIAO Rally; LI AUTO-W Recedes (AAStocks)
 
The HSI opened 43 points or 0.2% higher at 25,804. The HSCEI climbed 23 points or 0.3% to 9,051. The HSTECH rose 11 points or 0.2% to 5,546.In the FTSE China 50 Index review, CHINAHONGQIAO (01378.HK), CATL (03750.HK), and HENGRUI PHARMA (01276.HK) were included, while CSC (06066.HK), GWMOTOR (02333.HK), and LI AUTO-W (02015.HK) ......
04.12.25 - 02:30
FTSE China 50 Index Quarterly Review Includes CHINAHONGQIAO, CATL, HENGRUI PHARMA (AAStocks)
 
Um den gesamten Artikel unter aastocks.com zu lesen, klicken Sie bitte auf die Überschrift...
04.12.25 - 01:30
Ming Yu seeks a share of the drug sector limelight (Bamboo Works)
 
Led by a former research chief at drugs giant Hengrui, the Chinese biotech can boast solid credentials and big-name backers as it positions for a Hong Kong IPO Key Takeaways:    By Molly Wen A biotech founded by a former executive of Hengrui Pharma (600276.SH; 1276.HK) will be looking to bask in a halo effect..... The post Ming Yu seeks a share of the drug sector limelight appeared first on Bamboo Works....
25.11.25 - 03:15
S&P Global Mkt Intelligence Lists Top 10 Most Shorted HK Stocks Recently (AAStocks)
 
Stock Name│Change in Past 7 Days %│Short Interest %│Price Change in Past 7 Days %HENGRUI PHARMA (01276.HK) | +1.47% | 20.89% | -7.89%CHINA VANKE (02202.HK) | +1.38% | 17.46% | -3.68%ZTE (00763.HK) | -1.77% | 15.43% | -7.13%COSCO SHIP HOLD (01919.HK) | +0.21% | 14.19% | -4.87%CATL (03750.HK)│-2.98%│1......
18.11.25 - 09:00
S&P Global Mkt Intelligence Lists Top 10 Most Shorted HK Stocks Recently (AAStocks)
 
Stock Name│Change in Past 7 Days %│Short Interest %│Price Change in Past 7 Days %HENGRUI PHARMA (01276.HK) | 1.64% | 19.42% | 2.36%ZTE (00763.HK) | -0.32% | 17.20% | -2.98%CHINA VANKE (02202.HK) | 0.42% | 16.08% | 1.16%CATL (03750.HK) | -0.05% | 15.98% | -2.95%COSCO SHIP HOLD (01919.HK) | -0.12% | 13.98% | -0.2......
11.11.25 - 04:45
S&P Global Market Intelligence Lists Top 10 Shorted H Shrs Recently (AAStocks)
 
S&P Global Market Intelligence listed the top ten most shorted stocks in Hong Kong as of last Friday (7th). The data was calculated based on securities and finance datasets from S&P Global Market Intelligence. Stock Name | Change in Past 7 Days (%) | Short Selling Ratio (%) | Price Change in Past 7 Days (%)HENGRUI PHARMA......
27.10.25 - 12:36
Hengrui Pharma Reports Steady Growth in Q3 2025 Driven by Innovation and Global Expansion (PR Newswire)
 
SHANGHAI, Oct. 27, 2025 /PRNewswire/ -- Hengrui Pharma (600276.SH; 01276.HK) reported revenue of RMB23.20 billion for the first three quarters of 2025, up 14.85% year-on-year. Net profit attributable to shareholders was RMB5.75 billion, increased by 24.50% compared with the same period......
20.10.25 - 14:18
Corporate News: Hengrui Pharma (EQS)
 
Live vom ESMO | Hengrui präsentiert erstmals einen Messestand mit wegweisenden Daten und zeigt die aufkommende Innovationskraft der Pharmaindustrie...
20.10.25 - 09:21
Corporate News: Hengrui Pharma (EQS)
 
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma’s Emerging Innovation Power...
20.10.25 - 08:24
Live from ESMO | Hengrui Debuts Exhibition Booth with Landmark Data Showcasing Pharma′s Emerging Innovation Power (PR Newswire)
 
BERLIN, Oct. 20, 2025 /PRNewswire/ -- From October 17 to 21, the European Society for Medical Oncology (ESMO) Annual Congress convened in Berlin, bringing together global leaders in oncology and pharmaceutical innovation. Representing China's advancing biopharmaceutical landscape, Hengrui......
>Behalte deine Investments mit realtime Kursen & News im Blick. Finde neue spannende Aktien! Registriere Dich und werde Mitglied!
Zitat des Tages: Notwendigkeit ist bei weitem stärker als die Kunst. - Aischylos
>Aktien | >Anleihen | >ETFs | >Fonds | >Branchen | >Länder | >Themen | >Redaktionen
Partner:    >TradegateBSX Börse | >Dukascopy | >TradingView | >Boersentreff- Partner

Börsentreff auf Facebook | Börsentreff auf X | Börsentreff auf Instagram

Copyright @ Boersentreff.de - Die Märkte im Blick!